Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sana Biotechnology, Inc. (SANA)

Sana Biotechnology Q2 net loss narrows to $63.6 million from $93.8 million a year earlier

Positive Impact 3 of 5 earnings Written later

Sana Biotechnology reported second-quarter 2026 results with a net loss of $63.6 million, or $0.22 per share, compared with $93.8 million, or $0.39 per share, a year earlier; the prior-year figure included a $44.6 million impairment of long-lived assets. Cash, cash equivalents, and marketable securities were $160.5 million at June 30, 2026, and the company said its cash runway extends into mid-2027.

Key points

  • Q2 2026 net loss of $63.6 million ($0.22 per share) vs. $93.8 million ($0.39 per share) in Q2 2025; Q2 2025 included a $44.6 million impairment charge
  • Cash, cash equivalents, and marketable securities of $160.5 million at June 30, 2026, up from $138.4 million at December 31, 2025, after $93.3 million in net equity proceeds
  • Mayo Clinic made a $25.0 million equity investment in connection with a collaboration to advance SC451
  • Company expects to file an IND and begin a Phase 1/2 trial for SC451 and generate first-in-human SG293 data as early as this year

The filing

CompanySana Biotechnology, Inc. (SANA)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:09 PM ET
Accession number0001193125-26-342371

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.